Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darusentan in resistant systolic hypertension (DORADO-EX)
NCT00353574Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2006
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of darusentan in resistant hypertension (RH), sponsored by Gilead Sciences. Started Sep 2006; status: terminated.
02
Drugs
darusentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT00353574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00353574.